SPX Gestao de Recursos Ltda Takes $1.22 Million Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

SPX Gestao de Recursos Ltda purchased a new stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 10,000 shares of the biotechnology company's stock, valued at approximately $1,216,000.

A number of other hedge funds have also bought and sold shares of SRPT. Manchester Capital Management LLC boosted its holdings in shares of Sarepta Therapeutics by 86.6% in the 4th quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company's stock valued at $29,000 after acquiring an additional 110 shares during the last quarter. MassMutual Private Wealth & Trust FSB boosted its holdings in shares of Sarepta Therapeutics by 169.6% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company's stock valued at $30,000 after acquiring an additional 156 shares during the last quarter. Sunbelt Securities Inc. boosted its holdings in shares of Sarepta Therapeutics by 446.2% in the 3rd quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company's stock valued at $35,000 after acquiring an additional 232 shares during the last quarter. Huntington National Bank boosted its holdings in shares of Sarepta Therapeutics by 150.9% in the 3rd quarter. Huntington National Bank now owns 291 shares of the biotechnology company's stock valued at $36,000 after acquiring an additional 175 shares during the last quarter. Finally, Newbridge Financial Services Group Inc. purchased a new stake in Sarepta Therapeutics during the fourth quarter worth $36,000. Institutional investors and hedge funds own 86.68% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

SRPT has been the topic of several analyst reports. StockNews.com lowered shares of Sarepta Therapeutics from a "buy" rating to a "hold" rating in a research report on Wednesday, November 20th. Piper Sandler dropped their price target on shares of Sarepta Therapeutics from $200.00 to $182.00 and set an "overweight" rating on the stock in a research report on Wednesday, November 27th. HC Wainwright restated a "sell" rating and set a $75.00 price target on shares of Sarepta Therapeutics in a research report on Thursday, February 27th. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Sarepta Therapeutics in a research report on Tuesday, February 11th. They set a "hold" rating and a $136.00 price target on the stock. Finally, Needham & Company LLC restated a "buy" rating and set a $202.00 price target on shares of Sarepta Therapeutics in a research report on Thursday, February 27th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $170.41.

Insiders Place Their Bets

In other news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the business's stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $124.84, for a total value of $1,310,820.00. Following the sale, the director now directly owns 22,840 shares of the company's stock, valued at approximately $2,851,345.60. The trade was a 31.49 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 7.70% of the stock is owned by insiders.

Sarepta Therapeutics Trading Down 1.0 %

SRPT stock traded down $0.99 during trading on Wednesday, reaching $99.72. 292,189 shares of the stock were exchanged, compared to its average volume of 911,215. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. The business has a 50 day moving average price of $113.27 and a 200-day moving average price of $120.70. Sarepta Therapeutics, Inc. has a 1 year low of $97.91 and a 1 year high of $173.25. The firm has a market capitalization of $9.68 billion, a price-to-earnings ratio of 79.73 and a beta of 0.79.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.